Project Grant HT94252310107
Award Date
7/1/23
Completion Date
6/30/27
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
This $961,118 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at The Johns Hopkins University to target gut bacterial androgen production in order to reverse abiraterone resistance in metastatic prostate cancer. The 3-year award, beginning September 1, 2024, will enable the university to conduct innovative scientific studies aimed at developing treatments to improve health outcomes for military...
The Johns Hopkins University was awarded a $1,228,125 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research titled "PSMA-TARGETED ACTIVATED MYELOID CELLS AS A NOVEL PROSTATE CANCER IMMUNOTHERAPY" from September 2021 through September 2024. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $271,697 Project Grant to The Johns Hopkins University on Sep 1, 2024. The grant funds research to "TARGET GUT BACTERIAL ANDROGEN PRODUCTION TO REVERSE ABIRATERONE RESISTANCE IN METASTATIC PROSTATE CANCER". This research aims to develop new treatments for metastatic prostate cancer by investigating the role of gut bacteria in androgen production and resistance to certain cancer...
This $232,878 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research by The Johns Hopkins University to explore the role of epitranscriptomics in the evolution of neuroendocrine prostate cancer. The award, with a performance period from June 1, 2025 to May 31, 2027, will fund advanced biomedical research investigating innovative approaches to disease prevention, diagnosis, treatment, and...
This $484,013 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of "PSMA-TARGETED MULTIPARAMETRIC ULTRASOUND" research at The Johns Hopkins University. The award period runs from August 1, 2024 to July 31, 2026. The project aims to advance biomedical research and innovative medical solutions relevant to military personnel and the broader public. As a leading research institution, The...
This $1,473,751 federal Project Grant award, issued on August 15, 2024 by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports research by The Johns Hopkins University to investigate the influence of the tumor immune microenvironment and microbiome on prostate cancer immunotherapy response in Black men. The 3-year research initiative aims to transform healthcare through innovative and impactful medical research focused...
This $1,406,799 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports The Johns Hopkins University's research to develop real-time localization techniques using near-infrared fluorophores to guide robotic-assisted radical prostatectomy procedures. The 3-year award, running from August 1, 2024 to July 31, 2027, will enable Johns Hopkins to conduct innovative biomedical research to improve surgical outcomes and...
This $459,932 federal Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) will fund research by The Johns Hopkins University to investigate mechanisms of prostate cancer aggressiveness and metastasis. The research aims to uncover new insights into cribriform lesions, a potentially aggressive form of prostate cancer. This 2-year award from June 2025 to May 2027 will support the university's expert biomedical...
The Johns Hopkins University was awarded a $1,170,746 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to investigate the polyaneuploid cancer cell state and its role in mediating multitherapy resistance in cancer. The three-year award, effective August 15, 2022 through August 14, 2025, will support research into transforming healthcare for service members and the public through innovative biomedical...
The Johns Hopkins University will utilize $1.473 million from the Defense Health Agency under the Military Medical Research and Development program to conduct the "UTILIZING B7-H3 TARGETED THERAPEUTICS TO PREVENT LETHAL PROSTATE CANCER: THE HELP ELUCIDATE & ATTACK LONGITUDINALLY (HEAL) PROSTATE CANCER TRIAL COHORT" project from July 2023 to June 2026. The University will perform research to develop targeted therapeutics aimed at preventing lethal prostate cancer through the HEAL...